ArticleApplied biochemistry and biotechnology2026
USP7 Stabilizes MESP1 To Promote the Malignant Progression of Non-Small Cell Lung Cancer.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, necessitating the identification of novel therapeutic targets. Mesoderm posterior bHLH transcription factor 1 (MESP1) has been implicated in various developmental processes, but its role in cancer, particularly NSCLC, is poorly understood. Given the emerging evidence linking MESP1 to cellular processes relevant to cancer biology, investigating its regulatory mechanisms in NSCLC could provide critical insights for developing new therapies. This study employed quantitative real-time PCR (qRT-PCR) to assess the mRNA levels of MESP1, ubiquitin specific peptidase 7 (USP7), and clusters of differentiation 163 (CD163). Western blotting was used to analyze the protein expression of MESP1 and USP7. Cellular proliferation was evaluated through colony-forming assays, while apoptosis was quantified using flow cytometry. Mitochondrial membrane potential was measured by JC-1 staining, and reactive oxygen species (ROS) levels were also analyzed via flow cytometry. Additionally, colorimetric assays were utilized to determine malondialdehyde (MDA), total iron, and Fe
Indexed as
Identifiers
41563568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.